Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics, Inc. (DE:8NE)
:8NE
Total Valuation
Lisata Therapeutics has a market cap or net worth of €19.11M. The enterprise value is €2.02M.
Market Cap€19.11M
Enterprise Value€2.02M
Share Statistics
Lisata Therapeutics has 8,598,204 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,598,204
Owned by Insiders8.05%
Owned by Institutions2.52%
Financial Efficiency
Lisata Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -73.32%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-73.32%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee38.46K
Profits Per Employee-768.65K
Employee Count26
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lisata Therapeutics is -1.24. Lisata Therapeutics’s PEG ratio is >-0.01.
PE Ratio-1.24
PS Ratio0.00
PB Ratio0.59
Price to Fair Value0.84
Price to FCF-0.93
Price to Operating Cash Flow-0.90
PEG Ratio>-0.01
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 1.00M and earned -19.98M in profits. Earnings per share was -2.40.
Revenue1.00M
Gross Profit826.00K
Operating Income-22.41M
Pretax Income-20.78M
Net Income-19.98M
EBITDA-20.61M
Earnings Per Share (EPS)-2.40
Cash Flow
In the last 12 months, operating cash flow was -19.36M and capital expenditures 0.00, giving a free cash flow of -19.36M billion.
Operating Cash Flow-19.36M
Free Cash Flow-19.36M
Free Cash Flow per Share-2.25
Dividends & Yields
Lisata Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.24
52-Week Price Change-24.48%
50-Day Moving Average1.97
200-Day Moving Average2.47
Relative Strength Index (RSI)59.36
Average Volume (3m)0.00
Important Dates
Lisata Therapeutics upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Lisata Therapeutics as a current ratio of 6.16, with Debt / Equity ratio of 0.46%
Current Ratio6.16
Quick Ratio6.16
Debt to Market Cap0.00
Net Debt to EBITDA0.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lisata Therapeutics has paid -798.00K in taxes.
Income Tax-798.00K
Effective Tax Rate0.04
Enterprise Valuation
Lisata Therapeutics EV to EBITDA ratio is -0.42, with an EV/FCF ratio of -0.45.
EV to Sales8.75
EV to EBITDA-0.42
EV to Free Cash Flow-0.45
EV to Operating Cash Flow-0.45
Balance Sheet
Lisata Therapeutics has €31.25M in cash and marketable securities with $137.00K in debt, giving a net cash position of -€31.11M billion.
Cash & Marketable Securities€31.25M
Total Debt$137.00K
Net Cash-€31.11M
Net Cash Per Share-€3.62
Tangible Book Value Per Share€3.50
Margins
Gross margin is 86.80%, with operating margin of -2240.90%, and net profit margin of -1998.50%.
Gross Margin86.80%
Operating Margin-2240.90%
Pretax Margin-2078.30%
Net Profit Margin-1998.50%
EBITDA Margin-2060.90%
EBIT Margin-2240.90%
Analyst Forecast
The average price target for Lisata Therapeutics is €13.84, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€13.84
Price Target Upside540.84% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―